American Academy of CME

OACs and Patients with Malignancies (Part 3 of 3)

Overview / Abstract:	Direct acting oral anti-coagulants (DOACs) are a newer class of medications with emerging clinical recommendations and evidence for safe use. Cardiologists and pharmacists have key roles to play as part of the care team to help ensure efficacy and safety of DOACs within the severely ill patient population.
Expiration	Jul 27, 2023
Discipline(s)	Pharmacy CPE, Physician CME
Format	Online
Credits / Hours	.25
Accreditation	ACCME,ACPE
Presenters / Authors / Faculty	Maya R. Chilbert, PharmD, BCCP Clinical Assistant Professor University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY Elaine M. Hylek, MD, MPH Professor, Boston University School of Medicine, Boston, MA Attending, Boston Medical Center, Boston, MA
Activity Specialities / Related Topics	Cardiology / Cardiovascular, Medication Safety, Nephrology, Oncology / Cancer / Radiation Therapy, Pharmacology, Primary Care
Sponsors / Supporters / Grant Providers	Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.
Keywords / Search Terms	American Academy of CME DOACs Oncology Malignancies Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map